Treatment of major depressive disorder and treatment resistant depression with 5-MeO-DMT: Impact of 25 years of non-traditional public scientific communication and education on clinical development and commercialization

Over the past 25 years, informal and underground use of 5-MeO-DMT has generated substantial, though underrecognized, knowledge about its potential to alleviate depressive symptoms. Traditional drug development, with structured trials and regulatory milestones, rarely incorporates findings from these alternative routes. Legal and regulatory barriers have delayed formal clinical investigation, while public channels and Indigenous knowledge have driven grassroots support and anecdotal evidence of therapeutic benefit. The article identifies critical communication gaps hindering integration of 5-MeO-DMT into mainstream psychiatry and advocates for transparent data-sharing models that incorporate existing informal knowledge.

Study at a glance

Abstract

Over the past 25 years, the use of 5-MeO-DMT in informal and underground settings has contributed a substantial, yet underrecognized, body of knowledge relating to the efficacy of 5-MeO-DMT in alleviating depressive symptoms. Traditional models of drug development, typically characterized by structured trials and regulatory milestones, rarely consider findings from these alternative routes. The legal and regulatory barriers surrounding psychedelic compounds have delayed formal clinical investigation, while public channels and Indigenous knowledge have driven grassroots support and anecdotal evidence of therapeutic benefit. This article identifies critical communication gaps hindering the integration of 5-MeO-DMT into mainstream psychiatry, advocating for transparent data-sharing models that incorporate existing informal knowledge.